Maxwell Skor
Stock Analyst at Morgan Stanley
(1.50)
# 3,443
Out of 4,969 analysts
6
Total ratings
80%
Success rate
-7.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $143.50 | +0.35% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $200.02 | +24.99% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $2.99 | +301.34% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.87 | +434.76% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.04 | +241.35% | 2 | Nov 20, 2024 |
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $143.50
Upside: +0.35%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $200.02
Upside: +24.99%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $2.99
Upside: +301.34%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.87
Upside: +434.76%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.04
Upside: +241.35%